English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Cardiovascular disease (CVD) still determines the healthstatus of the vast majority of industrialized countries around the world. In a few years, Eastern European countries have significantly higher total and CVD mortality rates when compared to the Western European ones. Evidence-based lifestyle interventions, as nonpharmacological approaches, leading to changes in diet, physical activity and functional parameters can produce modest but clinically significant weight loss, reduce the prevalence of type 2 diabetes mellitus and improve cardiovascular risk factors and mortality for the people who are not overweight. In the viewpoint of pharmacological therapy of CVDs, the use of ultra short acting antagonists of beta-1adrenoceptors, i.e. the compounds containing carboxy group (drawn by dashed line in Scheme) and 2-hydroxypropane-1,3-diyl connecting chain in their chemical structure, could be very beneficial. For example, clinical studies indicated that the efficacy of esmolol (Scheme) is equivalent to that of propranolol and verapamil for control of supraventricular tachycardia and to sodium nitroprusside for control of postoperative hypertension. Esmolol has also been shown to control heart rate and blood pressure during episodes of acute myocardial ischemia. Due to its

Preliminary In vitro Investigation of Antioxidant Potential of Ultra Short Acting Arylcarbamoyloxy-aminopropanols Containing N-Phenylpiperazine Moiety